Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30790876 | 0.88 | DPP4 (0.42) | ABCB1GPR119KDM4EPKMUSP30 | |
| SCHEMBL13759689 | 0.87 | ABCB1 (0.40) | ABCB1GPR119KDM4EPKMSMYD2 | |
| SCHEMBL31224155 | 0.87 | ABCB1 (0.40) | ABCB1GPR119KDM4EPKMSMYD2 | |
| SCHEMBL17948125 | 0.85 | ABCB1 (0.38) | ABCB1GPR119KDM4EPKMSMYD2 | |
| SCHEMBL1769258 | 0.85 | ABCB1 (0.38) | ABCB1GPR119KDM4EPKMUSP30 | |
| SCHEMBL29007758 | 0.85 | ABCB1 (0.38) | ABCB1GPR119KDM4EPKMUSP30 | |
| SCHEMBL31224004 | 0.84 | ABCB1 (0.37) | ABCB1GPR119KDM4EPKMSMYD2 | |
| SCHEMBL25581981 | 0.84 | STS (0.37) | ABCB1GPR119KDM4EPKMUSP30 | |
| SCHEMBL31224890 | 0.83 | ABCB1 (0.39) | ABCB1GPR119KDM4EPKMUSP30 | |
| SCHEMBL1769372 | 0.83 | ABCB1 (0.36) | ABCB1GPR119KDM4EPKMSMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560434-B2 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560434-B2 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, NSUN3, POLR2H | ABCB1 2197/4885GPR119 1673/4885KDM4E 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.